Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Patel on Sequencing Therapy in Rectal Cancer

November 28th 2019

Timil Patel, MD, discusses an optimal sequencing strategy in rectal cancer.

FDA Grants Priority Review to Pemigatinib for FGFR2+ Cholangiocarcinoma

November 27th 2019

The FDA has granted a priority review to a new drug application for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements.

Dr. Rajdev on the Use of Somatostatin Analogs in Neuroendocrine Tumors

November 23rd 2019

Lakshmi N. Rajdev, MD, discusses the use of somatostatin analogs in patients with neuroendocrine tumors.

Atezolizumab Plus Bevacizumab Extends Survival in Frontline HCC

November 23rd 2019

The frontline combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) reduced the risk of disease progression or death by 42% compared with sorafenib (Nexavar) in patients with unresectable hepatocellular carcinoma.

Dr. Kaubisch on the REACH Trials in HCC

November 21st 2019

Andreas Kaubisch, MD, discusses the phase III REACH and REACH-2 trials in advanced hepatocellular carcinoma.

Dr. Ocean Discusses the Use of ctDNA in Pancreatic Cancer

November 20th 2019

Allyson Ocean, MD, discusses the use of circulating tumor DNA in pancreatic cancer.

Dr. Shah on Biomarkers in Gastric/GEJ Cancer

November 19th 2019

Manish A. Shah, MD, discusses biomarkers in gastric and gastroesophageal junction cancer.

Novel Therapy May Boost Efficacy of Chemotherapy Backbone in mCRC

November 18th 2019

In a phase III trial, investigators are examining if arfolitixorin can supplant leucovorin calcium, a widely used component of combination regimens in patients with metastatic colorectal cancer.

Dr. Kim on Treatment for BRAF-Mutant Colon Cancer

November 16th 2019

Richard Kim, MD, discusses treatment options for BRAF-mutant colon cancer.

Dr. Hidalgo Medina on Neoadjuvant Therapy in Pancreatic Cancer

November 16th 2019

Manuel Hidalgo Medina, MD, PhD, discusses the emergence of neoadjuvant chemotherapy and radiation in pancreatic cancer.

Rising Incidence of Fatty Liver Disease Holds Implications for Trends in HCC

November 13th 2019

Nonalcoholic fatty liver disease, a risk factor linked to the development of hepatocellular carcinoma and increased mortality, is growing in clinical significance.

Dr. Ocean on Efforts to Improve Early Detection in Pancreatic Cancer

November 12th 2019

Allyson Ocean, MD, discusses efforts to improve early detection rates in pancreatic cancer.

Dr. Eng on Unmet Needs in Early-Onset CRC

November 12th 2019

Cathy Eng, MD, FACP, FASCO, discusses unique barriers facing patients with early-onset colorectal cancer.

Varlitinib Misses PFS, ORR Endpoints in Biliary Tract Cancer

November 12th 2019

Varlitinib combined with capecitabine did not improve progression-free survival nor overall response rate compared with capecitabine/placebo as a second-line treatment in patients with biliary tract cancer.

FDA Grants Priority Review to Nivolumab/Ipilimumab in Advanced HCC

November 11th 2019

The FDA has granted a priority review designation to a supplemental biologics license application for the combination of nivolumab and ipilimumab for the treatment of patients with advanced hepatocellular carcinoma who received prior therapy with sorafenib.

Rapid Progress in HCC Leads to Sequencing Challenges

November 10th 2019

Andreas Kaubisch, MD, sheds light on systemic therapies available in liver cancer and some of the practice-changing phase III trials that have read out in the space.

Avelumab Falls Short as Frontline Maintenance for Gastric/GEJ Cancer

November 9th 2019

Avelumab did not improve overall survival as frontline maintenance following induction chemotherapy in patients with unresectable, locally advanced, or metastatic HER2-negative gastric or gastroesophageal junction cancer.

Expert Highlights Progress and Next Steps in Early Pancreatic Cancer

November 6th 2019

Allyson Ocean, MD, discusses pivotal trials in early pancreatic cancer, the need for genetic testing, and other research efforts focused on improving patient outcomes.

Dr. Rajdev on the Difference Between Cancers and Carcinomas in NETs

November 6th 2019

Lakshmi N. Rajdev, MD, an associate professor, Department of Medicine (Oncology), at Albert Einstein College of Medicine, Montefiore Medical Center, discusses the difference between cancers and carcinomas in neuroendocrine tumors (NETs).

Novel Strategies Progress Through mCRC Pipeline

November 6th 2019

Ryan B. Corcoran, MD, PhD, discusses emerging therapeutics for patients with relapsed/refractory colorectal cancer.